Strasbourg biotech appoints ceo

Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection

Polyplus-transfection, a Strasbourg-based biotechnology firm developing solutions for scientists working in molecular and cell biology, has appointed Mark Bloomfield as chief executive.

Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.

Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.



Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.

‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.

You may also like

Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Research & Development

Polyplus-transfection raises €2.5m in funding

Will enable the firm to expand its therapeutic research activities
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Pharmaceutical

White paper: Leadership as the missing control in the Pharmaceutical Quality System (PQS)

Why senior management determines the effectiveness of the pharmaceutical quality system
Subscribe now